Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cannabis Science has announced that the choice of initial cannabis-based pharmaceutical for FDA clinical trials has been made. The company has reported several possible drugs for FDA clinical trials. Based on extensive studies, Cannabis Science has decided to contract with a group based in Colorado to handle the company’s FDA filings.
Subscribe to our email newsletter
Robert Melamede, president and CEO of Cannabis Science, said: “We are in the final stages before Cannabis Science files with the FDA for clinical trials. There is a massive amount of Cannabis research that is available. Cannabis is one of the only drugs that have little or no negative side effects when used medically.
“We will request that the FDA consider this and other facts when examining our application. We have a great team of FDA experts and scientific minds to make sure that every step we take is inline with FDA requirements”
Richard Cowan, director and CFO of Cannabis Science, said: “We have decided to give this interim report due to the overwhelming interest we have been receiving in the US and around the World from existing and potential investors. In the next few days we will announce more specifics regarding our first FDA application.”
Cannabis Science has reported that it has successfully identified and negotiated medical cannabis growing operations to provide material for basic and clinical research and identified and negotiated for several strains of medical cannabis for initial drug formulations.
The company has also successfully identified cloning procedures to mass-produce exact strains in a controlled environment for compatibility with FDA standards.
It has established analytical procedures for manufacturing reproducible, high-quality cannabis extracts in order to meet the anticipated high demand and also identified and is implementing several manufacturing opportunities for standardized production protocols for large-scale rapid mass production.
Moreover, it has also successfully identified clinical trials facilities and doctors to handle clinical trials and negotiated several jurisdictional licensing and distribution agreements with potential partners around the World.